Formulating Relief for RA & ITP
PRTX-100 is positioned to address a major unmet need in the autoimmune sector with Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP)
About Protalex
Protalex is a biotechnology company developing a new class of drugs with the potential to revolutionize the treatment of autoimmune diseases.
Autoimmune Diseases
Today in the US, millions of individuals suffer from autoimmune diseases with Rheumatoid Arthritis and Immune Thrombocytopenia representing both large and niche markets.
Leadership Team
Protalex has an Experienced Management with committed support from an expert Scientific Advisory Board
Product Pipeline
